Genomics | News

JUL.04
2022

Event News

Kaohsiung Veterans General Hospital Departmental Seminar: Progress and Prospects in Precision Medicine

高雄榮民總醫院醫研部科會演講：精準醫療進行式與展望時間：7/8(五) am 8:30 地點：高雄榮民總醫院醫研部講者：前瞻技術發展事業群研發總監陳建文博士

主題

精準醫療進行式與展望

講者

陳建文博士前瞻技術發展事業群研發總監

時間

7/8(五) am 8:30

地點

高雄榮民總醫院醫研部

簡介

Part 1 精準醫療的歷史

2012年的台灣人體資料庫，和基米合作迄今已經10年，和中研院共同開發分析流程，分析了超過1500健康人的全基因位點資料，做為全球唯一華人世代追蹤，並且垂直整合和資料釋出的人體生物資料庫，提供研究者非常完整的背景資料庫，為台灣發展精準醫療提供最堅強的基礎和後盾，而緊接在後的2016年底台灣癌症登月計畫，迄今收案超過1000人，基米得以參與並開啟最初的癌症精準醫療計畫。

Part 2 現在進行式

基米擁有全台灣最齊全的illumina和三代定序機台，同時具備TAF認證核心實驗室，並以臨床研究蓄積多年的經驗和能量，正式進軍臨床市場，首站就是Illumina TSO 500，illumina最大的癌症檢測panel，可以檢測多達500種已知癌症基因，應用範圍廣，基米針對ctDNA內部測試，並已完成靈敏度和再現性，預計年底會申請LDTS，成為首個完成TSO 500癌症檢測技術的團隊。在分析方面基米秉持著和Qiagen多年合作夥伴關係，使用Qiagen clinical insight系統，得以產出具有臨床參考價值的精準用藥預測報告。

Part 3 未來展望

基龍米克斯與工研院合作興建全台第一座PIC/S GMP等級的商用核酸及多肽廠，預計10月取得ISO認證，目前進行中的計畫包含Neoantigen，核酸佐劑，並且引進Olink高通量proteomics系統，為臨床多體學開啟嶄新道路，並且獨家引進高通量10x Chromium X系統，冀望能夠成為高榮在精準醫學這條路上緊密的合作夥伴。

Genomics Partners with Vacino Biotech to Venture into Nucleic Acid New Drug Development, Unveiling a New Page in Domestic Autonomy

Genomics Bioscience & Technology Co. Ltd., a leading domestic genetic sequencing company (referred to as "Genomics", stock code: 4195), signed a memorandum of cooperation today (July 13) with Vacino Biotech Biomedical. (referred to as “Vacino Biotech”), combining Vacino Biotech's core independent R-MOD single-strand nucleic acid modification technology to develop a new type of drug for Alzheimer's disease, as well as Genomics' capability in key nucleic acid drug raw material synthesis and development. Genomics will assist Vacino Biotech in venturing into nucleic acid new drugs for Alzheimer's disease. Nucleic acid drugs are considered one of the mainstreams in the development of next-generation drugs. This collaboration not only marks a new chapter in Taiwan's nucleic acid industry's autonomy but also provides an opportunity for Taiwan to contribute to the development of new drugs for treating Alzheimer's disease.

JUL.13
2022

Genomics Shareholders' Meeting Approves NT$0.2 Stock Dividend and Election of Director

Genomics Bioscience & Technology Co. Ltd., a leading domestic company in genetic sequencing (referred to as “Genomics”, stock code: 4195), held its annual shareholders' meeting today (24th) for the year 2022. During the meeting, the company acknowledged the 2021 operating report, financial statements, and profit distribution proposal. They also approved the distribution of a stock dividend of NT$0.2 per share from the capital surplus. The shareholders' meeting approved amendments to the company's articles of association and rules of shareholder meetings. They also elected one director, with Lin Shih Chia, the General Manager of TaiAn Technologies being elected to the position.

JUN.24
2022

Explore Other News

goldennet

Kaohsiung Veterans General Hospital Departmental Seminar: Progress and Prospects in Precision Medicine

Other News

Genomics Partners with Vacino Biotech to Venture into Nucleic Acid New Drug Development, Unveiling a New Page in Domestic Autonomy

Genomics Shareholders' Meeting Approves NT$0.2 Stock Dividend and Election of Director